受试者中至少50%无冠心病病史,随访大于等于12个月的随机对照试验入选本次分析。
Randomized controlled trials with a study population with at least 50% of the subjects having no history of coronary heart disease and 12 or more months of follow-up were included.
一级终点为无中风的生存,死亡和优于药物治疗,目前已入选了14例患者。
The primary endpoint in this arm is survival without stroke or death and superiority to medical therapy. This trial arm has enrolled 14 patients to date.
应用推荐